tetano
Editor, Senior Moderator
Int J Infect Dis
. 2020 Aug 20;S1201-9712(20)30670-6.
doi: 10.1016/j.ijid.2020.08.051. Online ahead of print.
CORTICOSTEROIDS IN THE TREATMENT OF SEVERE COVID-19 LUNG DISEASE: THE PULMONOLOGY PERSPECTIVE FROM THE FIRST UNITED STATES EPICENTER
Precious Macauley[SUP] 1 [/SUP], Alvaro Martin[SUP] 2 [/SUP], Oleg Epelbaum[SUP] 3 [/SUP]
Affiliations
Abstract
The SARS-CoV-2 pandemic has introduced the medical community to a lung disease heretofore unknown to most clinicians. In much of the discourse about COVID-19 lung disease, the more familiar clinical entity of ARDS has been used as the guiding paradigm. Reflecting on studies in ARDS, particularly that due to influenza, and on data from the SARS-CoV and MERS epidemics, many authorities, including within the discipline of infectious diseases, were initially passionate in their opposition to the use of corticosteroids for lung involvement in COVID-19. The voice of the pulmonology community-the community of lung experts-has continued to be among the quietest in this conversation. Herein we offer our perspective as academic pulmonologists who encountered COVID-19 in its first United States epicenter of New York City. We encourage a conceptual separation between early COVID-19 lung involvement and ARDS. We draw on history with other immune cell-mediated lung diseases, on insights from the SARS-CoV experience, and on frontline observations in an attempt to allay the skepticism towards corticosteroids in COVID-19 lung disease that is likely to persist even as favorable study results emerge.
Keywords: ARDS; COVID-19; Coronavirus; Corticosteroids; SARS.
. 2020 Aug 20;S1201-9712(20)30670-6.
doi: 10.1016/j.ijid.2020.08.051. Online ahead of print.
CORTICOSTEROIDS IN THE TREATMENT OF SEVERE COVID-19 LUNG DISEASE: THE PULMONOLOGY PERSPECTIVE FROM THE FIRST UNITED STATES EPICENTER
Precious Macauley[SUP] 1 [/SUP], Alvaro Martin[SUP] 2 [/SUP], Oleg Epelbaum[SUP] 3 [/SUP]
Affiliations
- PMID: 32829047
- DOI: 10.1016/j.ijid.2020.08.051
Abstract
The SARS-CoV-2 pandemic has introduced the medical community to a lung disease heretofore unknown to most clinicians. In much of the discourse about COVID-19 lung disease, the more familiar clinical entity of ARDS has been used as the guiding paradigm. Reflecting on studies in ARDS, particularly that due to influenza, and on data from the SARS-CoV and MERS epidemics, many authorities, including within the discipline of infectious diseases, were initially passionate in their opposition to the use of corticosteroids for lung involvement in COVID-19. The voice of the pulmonology community-the community of lung experts-has continued to be among the quietest in this conversation. Herein we offer our perspective as academic pulmonologists who encountered COVID-19 in its first United States epicenter of New York City. We encourage a conceptual separation between early COVID-19 lung involvement and ARDS. We draw on history with other immune cell-mediated lung diseases, on insights from the SARS-CoV experience, and on frontline observations in an attempt to allay the skepticism towards corticosteroids in COVID-19 lung disease that is likely to persist even as favorable study results emerge.
Keywords: ARDS; COVID-19; Coronavirus; Corticosteroids; SARS.